Solar D Sunscreen Claims Leave NAD With A Burn, IsoSensuals Claims Just Leave
This article was originally published in The Rose Sheet
Executive Summary
NAD refers its review of claims Solar D Skincare to the FTC after the firm declined to submit substantiating information. The IsoSensual supplement brand pulled its ad claims for vaginal, buttocks benefits.
You may also be interested in...
Industry Needs More Time To Comply With Sunscreen Testing, Labeling Rule
A "shortage of sunscreen products" could occur in summer 2012 unless FDA allows manufacturers six additional months to comply with the testing and labeling requirements imposed in a recent final rule, trade groups say.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.